Evidence map›Paper›PMID 31649658›Full record

ArticleFrontiers in microbiology2019

Marta Mellini, Elena Di Muzio, Francesca D'Angelo, Valerio Baldelli, Serena Ferrillo, Paolo Visca, Livia Leoni, Fabio Polticelli, Giordano Rampioni

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Evaluation of novel compounds as anti-bacterial or anti-virulence agents.Frontiers in cellular and infection microbiology · 2024
    Review
  6. Microbial Genomics: Innovative Targets and Mechanisms.Antibiotics (Basel, Switzerland) · 2023
    Review
  7. Article
  8. Alkyl-quinolone-dependent quorum sensing controls prophage-mediated autolysis inFrontiers in cellular and infection microbiology · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Drug Repurposing TargetingAntibiotics (Basel, Switzerland) · 2022
    Article
  13. RepurposingAntibiotics (Basel, Switzerland) · 2022
    Article
  14. Computational and Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2022
    Article
  15. Frontiers in microbiology · 2022
    Article
  16. Transcriptional Profiling of Pseudomonas aeruginosa Infections.Advances in experimental medicine and biology · 2022
    Review
  17. Article
  18. New Insight into Vitamins E and KAntimicrobial agents and chemotherapy · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Marta MelliniDepartment of Science, University Roma Tre, Rome, Italy.
Elena Di MuzioDepartment of Science, University Roma Tre, Rome, Italy.
Francesca D'AngeloDepartment of Science, University Roma Tre, Rome, Italy.
Valerio BaldelliDepartment of Science, University Roma Tre, Rome, Italy.
Serena FerrilloDepartment of Science, University Roma Tre, Rome, Italy.
Paolo ViscaDepartment of Science, University Roma Tre, Rome, Italy.
Livia LeoniDepartment of Science, University Roma Tre, Rome, Italy.
Fabio PolticelliDepartment of Science, University Roma Tre, Rome, Italy.
Giordano RampioniDepartment of Science, University Roma Tre, Rome, Italy.
Roma Tre University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of antibiotic resistant bacterial pathogens is increasing at an unprecedented pace, calling for the development of new therapeutic options. Small molecules interfering with virulence processes rather than growth hold promise as an alternative to conventional antibiotics. Anti-virulence agents are expected to decrease bacterial virulence and to pose reduced selective pressure for the emergence of resistance. In the opportunistic pathogen

Indexed as

anti-virulence strategyin silico screeningmolecular dockingnew therapeuticspimozidePqsRPseudomonas aeruginosaquorum sensing inhibition

Identifiers

PMID31649658
PMCPMC6796623
OpenAlexW2979577426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.